We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
XCELERON Launches Solution to FDA MIST
Product News

XCELERON Launches Solution to FDA MIST

XCELERON Launches Solution to FDA MIST
Product News

XCELERON Launches Solution to FDA MIST


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "XCELERON Launches Solution to FDA MIST"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

XCELERON has announced the launch of its solution to the FDA 'Safety Testing of Drug Metabolites' guidance (also known as MIST: 'Metabolites in Safety Testing').

The guidance, issued in February 2008, highlights the importance of obtaining human drug metabolite information in humans as early as possible. Xceleron's microtracer approach generates quantitative metabolism data from an existing Phase I study.

"Our MIST solution has been developed in collaboration with major drug developers. It cost-effectively provides a quantitative metabolite profile from a scheduled clinical Phase I study to determine if there are disproportionate human metabolites that need to be investigated further" commented Dr. Mike Butler, CEO, Xceleron.

The guidance states "metabolites that can raise a safety concern are those formed at greater than 10 percent of parent drug systemic exposure at steady state". It is recommended that in vivo metabolic evaluation in humans be performed as early as possible.
Advertisement